Zobrazeno 1 - 10
of 4 378
pro vyhledávání: '"BRAF MUTATION"'
Autor:
J. Steininger, C. Buszello, R. Oertel, M. Meinhardt, S. Schmid, K. Engellandt, S. Herold, S. Stasik, A. Ebrahimi, B. Renner, C. Thiede, I.Y. Eyüpoglu, G. Schackert, S. Beissert, F. Meier, J. Radke, D. Westphal, T. A. Juratli
Publikováno v:
Acta Neuropathologica Communications, Vol 12, Iss 1, Pp 1-12 (2024)
Abstract Epithelioid glioblastoma (eGB), a very aggressive and rare brain tumour, is associated with a dismal median overall survival. Effective therapies for patients with eGB, particularly with leptomeningeal dissemination, are still lacking. Here,
Externí odkaz:
https://doaj.org/article/0fb644eeacee4ed68b3f90f56d2e1371
Autor:
Lovisa Falkman, Anders Sundin, Britt Skogseid, Johan Botling, Yvette Bernardo, Göran Wallin, Liang Zhang, Staffan Welin, Ieva Lase, Kazhan Mollazadegan, Joakim Crona
Publikováno v:
Upsala Journal of Medical Sciences, Vol 129, Pp 1-7 (2024)
Background: Metastatic neuroendocrine carcinoma (NEC) is associated with short survival. Other than platinum-based chemotherapy, there is no clear standard regimen. Current guidelines suggest that combination treatment with BRAF-inhibitors should be
Externí odkaz:
https://doaj.org/article/e138f2357a1d4fe5ade89d82ea78a815
Autor:
Fausto Petrelli, Maria Antista, Lorenzo Dottorini, Alessandro Russo, Marcella Arru, Roberta Invernizzi, Mariangela Manzoni, Chiara Cremolini, Alberto Zaniboni, Ornella Garrone, Gianluca Tomasello, Michele Ghidini
Publikováno v:
Heliyon, Vol 10, Iss 17, Pp e36497- (2024)
Introduction: The molecular profile of colorectal cancer (CRC) plays a crucial role in understanding patient prognosis and treatment response. Within CRC, a distinct subgroup can be identified by the presence of the BRAF V600E mutation. This specific
Externí odkaz:
https://doaj.org/article/4eb10c4254cd437fbfa1d55b7078f35a
Autor:
Daniele Barbaro, Raffaella Forleo, Maria Antonietta Profilo, Paola Lapi, Carlotta Giani, Liborio Torregrossa, Elisabetta Macerola, Gabriele Materazzi
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
BackgroundTyrosine kinase inhibitors (TKIs) and immunotherapy have been proposed for advanced metastatic anaplastic thyroid cancer (ATC). We report a case of BRAF V600E-mutated ATC in which lenvatinib (L) plus pembrolizumab (P) enabled neoadjuvant tr
Externí odkaz:
https://doaj.org/article/ab46a37234e3452a9a44ca8fd2d0cf9c
Autor:
Yulu Chen, Ye Sang, Shiyong Li, Junyu Xue, Mengke Chen, Shubin Hong, Weiming Lv, Kartik Sehgal, Haipeng Xiao, Rengyun Liu
Publikováno v:
Translational Oncology, Vol 45, Iss , Pp 101991- (2024)
BRAF or RAS mutation-induced aberrant activation of the mitogen-activated protein kinase (MAPK) pathway is frequently observed in human cancers. As the key downstream node of MAPK pathway, ERK1/2 is as an important therapeutic target. GDC-0994 (ravox
Externí odkaz:
https://doaj.org/article/a06cafe2d8e1449ead38b4f0a66de4de
Publikováno v:
Thoracic Cancer, Vol 15, Iss 18, Pp 1454-1456 (2024)
Abstract Although dabrafenib plus trametinib has been approved for BRAF V600E mutation positive advanced non‐small cell lung cancer (NSCLC), data on its efficacy against uncommon BRAF mutations are still limited due to their rare frequency. We repo
Externí odkaz:
https://doaj.org/article/8304f5f801794ef8a5a47c81e64fabd0
Autor:
S. A. Yаrgunin, I. V. Reshetov, Ya. N. Shoykhet, S. I. Samoylova, O. Yu. Chukhrai, S. N. Pyatakov, V. S. Yаrgunin
Publikováno v:
Инновационная медицина Кубани, Vol 0, Iss 1, Pp 8-17 (2024)
Background: Cutaneous melanoma is an extremely aggressive disease with an unpredictable prognosis. Even among patients with similar tumor parameters and extent of surgical treatment, survival may vary. The extent of surgical resection of primary cuta
Externí odkaz:
https://doaj.org/article/2ed655b3f4d043a496a775181b29395b
Publikováno v:
eJHaem, Vol 5, Iss 1, Pp 247-250 (2024)
Abstract BRAF mutations are associated with a small number of hematologic malignancies, including hairy cell leukemia and histiocytic disorders. In addition, BRAF mutations have also been detected in low frequency in other B‐cell lymphomas, such as
Externí odkaz:
https://doaj.org/article/8e68575ed06343b181b23f3a039eeb44
Autor:
Anne Hansen Ree, Eirik Høye, Ying Esbensen, Ann-Christin R. Beitnes, Anne Negård, Linn Bernklev, Linn Kruse Tetlie, Åsmund A. Fretland, Hanne M. Hamre, Christian Kersten, Eva Hofsli, Marianne G. Guren, Halfdan Sorbye, Hilde L. Nilsen, Kjersti Flatmark, Sebastian Meltzer
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
The randomized METIMMOX trial (NCT03388190) examined if patients with previously untreated, unresectable abdominal metastases from microsatellite-stable (MSS) colorectal cancer (CRC) might benefit from potentially immunogenic, short-course oxaliplati
Externí odkaz:
https://doaj.org/article/a08572504c1241d5a365f6b0a359ede1
Publikováno v:
GMS Ophthalmology Cases, Vol 14, p Doc03 (2024)
Purpose: Colorectal cancers are common and have high mortality, and metastasis is common in follow up. Choroidal metastasis is encountered rarely in rectum cancers, and there is no previous case reported from Turkey. We present our patient who develo
Externí odkaz:
https://doaj.org/article/4abd51aa437e4637b8e439b8463cbda4